Renee Louis
About Renee Louis
Renee Louis serves as the Director of Business Development at Celerion, bringing extensive experience from various leadership roles in the clinical research and pharmaceutical industries. Over her career, she has held key positions at organizations such as Covance, Q² Solutions, and WORLDWIDE CLINICAL TRIALS, contributing to significant business growth and development.
Current Role at Celerion
Renee Louis serves as the Director of Business Development at Celerion, a position she has held since 2023. She operates within the Denver Metropolitan Area in a remote capacity. In this role, she focuses on expanding business opportunities and fostering relationships within the clinical research sector.
Previous Experience in Business Development
Renee Louis has extensive experience in business development across various organizations. She worked at Covance (legacy Tandem Labs) as Business Development Director from 2011 to 2016. Following this, she held the same title at Spaulding Clinical Research, LLC from 2017 to 2018, and at Q² Solutions from 2018 to 2022. Most recently, she was the Senior Director of Business Development Early Phase at WORLDWIDE CLINICAL TRIALS EARLY PHASE SERVICES from 2022 to 2023.
Educational Background
Renee Louis studied at the University of Arizona, where she earned a Bachelor of Science degree in Molecular and Cellular Biology. Her studies spanned from 1986 to 1991, providing her with a strong foundation in the biological sciences.
Awards and Recognition
Renee Louis has received notable awards for her contributions in the field of business development. In 2013, she was honored with the Largest Territory Growth Award for her exceptional performance in expanding business reach. Additionally, she was recognized as a Gem Club Recipient in the same year, acknowledging her outstanding contributions to her organization.
Early Career Experience
Renee Louis began her career in the scientific field as a Lab Technician at COBE Cardiovascular from 1991 to 1996. She transitioned into business development roles, including positions as a Toxicology Scientist II at Gambro BCT from 1996 to 2001, and as a Business Development Manager at Toxikon Corporation from 2001 to 2003, and Huntingdon Life Sciences from 2003 to 2008.